Galapagos slumps as H1 report offers limited visibility

Lakefront Biotherapeutics NV

24/07/2025 09:27

** Shares in Galapagos GLPG.AS fall 13% after the Amsterdam-listed drugmaker posted its H1 report with no update on cell therapy business future, cash outlook

** Degroof Petercam notes Galapagos' Jan-June net result turned to a loss of EUR 259 mln vs net profit a year ago given R&D expenses, fair value adjustments and net loss from discontinued operations

** With the update on the cell therapy business and cash burn outlook expected at Q3 results, the brokerage keeps a "hold" rating on the stock, citing lack of visibility on the path forward

** At end-H1 Galapagos cash balance was EUR 3.1 bln vs EUR 3.4 bln at end-2024

** The shares are down 13% at 0825 GMT, on track for their worst day in four years, if losses hold

($1 = 0.8501 euros)

 (Reporting by Vera Dvorakova)

 ((vera.dvorakova@thomsonreuters.com))